Nicoderm Cqnicotine

According to the FDA label: Use reduces withdrawal symptoms, including nicotine craving, associated with quitting smoking

30,911 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Nicoderm Cq in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Nicoderm Cq adverse event reports by reporter sex
SexReports
Female16,740
Male9,873
Unknown117

By Age Group

View age group data as a table
Nicoderm Cq adverse event reports by reporter age group
Age groupReports
0-17461
18-343,271
35-494,519
50-646,441
65-743,057
75+933

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Nicoderm Cq. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Nicoderm Cq adverse event reports by reported outcome
OutcomeReports
Non-Serious18,366
Other Serious8,949
Hospitalization5,346
Death1,724
Life-Threatening642
Disability369

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Nicoderm Cq. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Nicoderm Cq adverse event reports by year
YearReports
2004352
20053,367
20063,412
2007571
2008409
2009524
2010597
2011686
2012718
2013847
2014725
20152,713
20162,032
20171,621
20182,782
20191,904
20201,554
20211,413
20221,105
20231,148
20241,136
20251,080
2026 (partial)215

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Nicoderm Cq

In FDA adverse event reports that mention Nicoderm Cq, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026